EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts

Zhite Zhao, Yaohua Hu, Hui Li, Tong Lu, Xinglin He, Yifan Ma, Minli Huang, Mengyao Li, Lijun Yang, Changhong Shi

Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010555

DOI: 10.1136/jitc-2024-010555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 22.03.2025. Verfasst von Zhite Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Monoamine Oxidase, Wnt-5a Protein, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shaanxi Province Innovation Capability Support Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The interaction between stromal cells and the tumor immune microenvironment (TIME) is acknowledged as a critical driver in the progression of prostate cancer (PCa). Monoamine oxidase A (MAOA), a mitochondrial enzyme that catalyzes the degradation of monoamine neurotransmitters and dietary amines, has been linked to the promotion of prostate tumorigenesis, particularly when upregulated in stromal cells. However, the detailed mechanisms of MAOA’s interaction with TIME have not been fully elucidated.

Methods

We reanalyzed a single-cell sequencing dataset to evaluate the role of MAOA in the stroma, verify the impact of stromal MAOA alterations on CD8 + T cell responses by co-culturing stromal cells and immune cells in vitro. Furthermore, C57BL/6J mouse subcutaneous transplant tumor models and dual humanized mouse models were established to investigate the function of MAOA in vivo and the potential of its inhibitors for immunotherapy.

Results

Our study demonstrates that inhibiting MAOA in stromal cells facilitates the conversion of myofibroblastic cancer-associated fibroblasts (myCAFs), thereby improving the immunosuppressive environment of PCa. The strategic combination of MAOA inhibition with immune checkpoint inhibitors elicits a synergistic antitumor effect. Specifically, MAOA inhibition in stromal cells leads to increased production of WNT5A, which subsequently activates the cytotoxic capacity of CD8 + T cells through the Ca 2+ -NFATC1 signaling pathway.

Conclusions

Our findings highlight the critical role of MAOA in modulating cancer-associated fibroblasts within the PCa immune microenvironment, presenting a novel therapeutic strategy to augment the efficacy of immunotherapy for PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMonoamine OxidaseWnt-5a ProteinCancer-Associated FibroblastsImmunotherapyMaleAnimalsMiceHumansTumor MicroenvironmentMice, Inbred C57BLStromal CellsCell Line, Tumor

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapyProstate CancerTumor microenvironment - TME

Substanzen

Monoamine OxidaseWnt-5a ProteinWNT5A protein, human

Autor:innen und Institutionen

  • Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Fourth Military Medical University, Xi'an, Shaanxi, China changhong@fmmu.edu.cn.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xi'an, Shaanxi, China.

Förderung

  • Shaanxi Province Innovation Capability Support Plan
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, Z., Hu, Y., Li, H., Lu, T., He, X., Ma, Y., Huang, M., Li, M., Yang, L., & Shi, C. (2025). Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. Journal for ImmunoTherapy of Cancer, 13(3), e010555. https://doi.org/10.1136/jitc-2024-010555

Vancouver

Zhao Z, Hu Y, Li H, Lu T, He X, Ma Y, et al. Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010555. doi:10.1136/jitc-2024-010555

BibTeX
@article{Zhao2025,
  author = {Zhao, Zhite and Hu, Yaohua and Li, Hui and Lu, Tong and He, Xinglin and Ma, Yifan and Huang, Minli and Li, Mengyao and Yang, Lijun and Shi, Changhong},
  title = {Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {e010555},
  doi = {10.1136/jitc-2024-010555}
}
Kostenlos starten →